Found 25 All Conditions trials

Below is a list of actively recruiting clinical trials based on your search for "All Conditions"

18 years or above
All genders
Phase 3
Interventional
This is a Phase 3, parallel group, 2-arm, randomized, double blind, placebo-controlled, 52-week treatment study to assess the efficacy and safety of rilzabrutinib as a treatment for adult patients with active IgG4-RD.The purpose of this study is to measure time to IgG4-RD clinical disease flare, and other relevant efficacy endpoints …
18 years or above
All genders
Phase 3
Interventional
This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approximately 90 male and female participants ≥ 18 years of age with a confirmed diagnosis of primary wAIHA.Following a 4-week …
18 years - 80 years
All genders
Phase 2
Interventional
This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma.The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous (SC) lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with …
18 years - 75 years
All genders
Phase 2
Interventional
This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn's Disease (CD). The primary objective of this study is to assess the efficacy of different doses of SAR441566 compared with placebo in …
40 years - 85 years
All genders
Phase 4
Interventional
LPS18583 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 4 study with 2 treatment groups. The purpose of this study is to assess the effect of dupilumab compared with placebo on airway inflammation, resistance, and remodeling including mucus plugging and its association with improvement on lung function, exacerbations, and quality …
18 years or above
All genders
Phase 3
Interventional
The purpose of the study is to evaluate effectiveness and safety of riliprubart compared to placebo in adult with CIDP whose disease does not respond to available treatments. The study duration will be up to 25 months (about 2 years).
18 years - 75 years
All genders
Phase 2
Interventional
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis.This …
18 years or above
All genders
Phase 3
Interventional
 The purpose of the study is to evaluate effectiveness and safety of riliprubart compared to intravenous immunoglobulin (IVIg) in adult participants with CIDP who are receiving maintenance treatment with IVIg but continue to have physical challenges. The study duration will up to 25 months (about 2 years).
1 year - 25 years
All genders
Phase 3
Interventional
This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment.The purpose of this study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab compared with placebo, both administered by intravenous (IV) infusion, in participants with recently diagnosed Stage 3 …
All genders
Phase 2
Interventional
This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207).The study duration will be up to approximately 56 weeks per …
1 - 10 of 25